Bank of Montreal’s Sarepta Therapeutics SRPT Stock Holding History

Bank of Montreal’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$244K	Buy	+11,200	New	+$217K	﹤0.01%	2818
2025 Q4	–	Sell	-1,200	Closed	-$23.1K	–	3821
2025 Q3	$23.1K	Buy	+1,200	New	+$21.4K	﹤0.01%	3262
2019 Q1	–	Sell	-50,000	Closed	-$5.46M	–	4714
2018 Q4	$5.46M	Buy	+50,000	New	+$6.25M	0.01%	1035
2016 Q4	–	Sell	-55,700	Closed	-$3.42M	–	4183
2016 Q3	$3.42M	Sell	55,700 -76,600	-58%	-$2.32M	﹤0.01%	1257
2016 Q2	$2.52M	Buy	+132,300	New	+$2.45M	﹤0.01%	1389

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of Montreal's SRPT Position: Q1 2026 in Review

Bank of Montreal increased its Sarepta Therapeutics (SRPT) stake by 71% in Q1 2026, buying an estimated $207K and bringing the position to 25,815 shares worth $562K. The position accounts for ﹤0.01% of the portfolio, ranked #2339.

Bank of Montreal first reported a position in SRPT in Q2 2013 and has held it in 52 quarters since. The position peaked at $37.8M in Q1 2022. 341 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

Bank of Montreal held 25,815 shares of Sarepta Therapeutics worth $562K as of Q1 2026.
Bank of Montreal bought 10,685 Sarepta Therapeutics shares in Q1 2026, an estimated $207K.
Sarepta Therapeutics made up ﹤0.01% of Bank of Montreal's portfolio in Q1 2026, its #2339 holding.
Bank of Montreal first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 52 quarters since.
Bank of Montreal's Sarepta Therapeutics position peaked at $37.8M in Q1 2022.
341 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Bank of Montreal's 13F filing for Q1 2026, filed 13 May 2026.